This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from July and August.
- Why Oncology Programs Can't Rely On An Inside View Alone
- In Case You Missed Them: Recapping The FDA's Recent Guidances For Cell And Gene Therapies
- Repurposing Three FDA-Approved Drugs For A New Stroke Recovery Strategy
- Before Adding AI, Fix The Process
- Coalition Takes Guesswork Out Of Charcot-Marie-Tooth Disease Research With New Guidance
- How AI Will Reshape Study Start-Up
- Clinical Supply Systems Need IT General Controls
GUEST COLUMNISTS
-
![healthcare workers collaborate-GettyImages-2257620029]( "How AI Will Reshape Study Start-Up")
How AI Will Reshape Study Start-UpAI can help study start-up teams move from tracking delays to predicting risks—if human judgment, data quality, and governance stay central.
-
![online document verification, file management, data storage-GettyImages-2265259381]( "Clinical Supply Systems Need IT General Controls")
Clinical Supply Systems Need IT General ControlsValidating a clinical trial system does not prove it stays trustworthy. IT general controls can protect data, supply decisions and patient safety long after go-live.
-
![metal chain-GettyImages-638503806]( "Medical Affairs: The Missing Link To Oncology Drug Adoption")
Medical Affairs: The Missing Link To Oncology Drug AdoptionLearn how medical affairs can help oncology teams turn strong clinical evidence into real-world adoption by connecting development strategy with clinical practice.
-
![Teamwork, collaboration-GettyImages-2218614336]( "How Can We Influence Others For Better Outcomes In Clinical Research?")
How Can We Influence Others For Better Outcomes In Clinical Research?Learn how to use the Delphi method to build consensus and drive better decisions in clinical research — even when stakeholders start far apart.
-
![AI making money-GettyImages-2271467935]( "What Will Life Science Orgs Do When The AI Bill Comes Through?")
What Will Life Science Orgs Do When The AI Bill Comes Through?AI is transforming clinical development, but what happens when usage costs spike? Jon Newton explains how to govern it before the bill lands.
-
![Medical quality control-GettyImages-2072996733]( "Clinical Trial Standards — What They Are And Why They're Indispensable")
Clinical Trial Standards — What They Are And Why They're IndispensableClinical trial standards are essential. But to interpret changes, preserve meaning, and assess downstream impact, context is key.
-
![warehouse worker checking barcodes-GettyImages-2265704054]( "Last-Mile Lessons For Depot-To-Site Delivery")
Last-Mile Lessons For Depot-To-Site DeliveryDepot-to-site delivery is more than a courier handoff. See how reconciliation gaps, temperature risks, and mismatched SLAs can turn last-mile issues into trial delays.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
Turn AI Visibility Into Action: Build Explanation Layers For Different StakeholdersAI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
CLINICAL TRIAL WHITE PAPERS
-
![GettyImages-1146439597 data, research, tablet]( "The Evolution Of SDV, SDR, And RBQM In Clinical Trial Data Quality")
The Evolution Of SDV, SDR, And RBQM In Clinical Trial Data QualityExplore the inefficiency of complete SDV and how the adoption of technologies like centralized monitoring, remote SDR, and targeted SDV can enhance data integrity and cost-effectiveness.
-
Designing More Representative Trials Through Strategic Planning5/28/2025
Strategic planning for representative clinical trials improves outcomes, regulatory alignment, recruitment efficiency, and commercial value by ensuring study populations mirror real-world patients.
-
A Promising Rebound in Clinical Trials10/23/2024
This report explores how clinical trials bounced back in 2023 from their decline a year earlier despite continued geopolitical, regulatory, and pricing pressures.
-
The Importance Of A Maturity Model For Clinical Trial Transparency10/23/2024
A comprehensive maturity model for clinical trial disclosure and transparency offers companies a strategic tool to assess and enhance their practices in an increasingly complex regulatory environment.
-
Implications Of Assessing Overall Survival In Oncology Studies3/25/2026
New oncology standards mandate pre-specified survival analysis to catch long-term harm. Learn how to implement hazard ratio thresholds and the ICH E9(R1) framework for global compliance.
-
Patient-Reported Outcome In Oncology Clinical Trials4/17/2025
As cancer therapies grow more complex and personalized, patient-reported outcomes (PROs) have emerged as a vital component of oncology research and care.
CLINICAL TRIAL APP NOTES & CASE STUDIES
-
Delivering Complex Oncology Trials At Scale5/19/2026
Parexel delivered two complex, global Phase III prostate cancer trials by aligning site selection, logistics, imaging workflows, and RAM regulatory expertise—achieving faster enrollment and on‑time execution.
-
Accelerating A Global, FIH ADC Therapy Trial For Lung Cancer11/17/2025
Choose a development partner who can navigate global execution, ADC-specific challenges, and Project Optimus requirements so your first-in-human study is designed and positioned for success.
-
Biometric Services For Large Pharmaceutical Company7/31/2025
This case exemplifies the effectiveness of flexible staffing solutions in meeting the dynamic needs of the biopharmaceutical industry while maintaining control over project deliverables and timelines.
-
How A Biotech Startup Transformed Its Clinical Trial Supply Management2/25/2026
Don’t let your trial get lost in the shuffle of legacy vendors. See how a high-touch, consultative approach can protect your study’s future.
-
Solutions To The Challenges Of Oncology Trials5/6/2025
This significant Phase III trial, one of the largest global studies in head and neck cancer, faced considerable challenges including enrollment delays and an intricate study design.
-
How A Leading Chinese Biopharmaceutical Company Modernized Clinical Operations7/15/2026
A growing biopharma pipeline needed better document oversight. Learn how automation and centralized tracking improved compliance and trial visibility.
NEWSLETTER ARCHIVE
- 09.22.26 -- Sponsors Take Control: Faster Builds, Cleaner Data, Audit-Ready Trials
- 09.21.26 -- The SIP Problem Is Bigger Than SIP
- 09.18.26 -- The Promise Of MRD-Guided CAR-T Treatment
- 09.18.26 -- Patients Are Dropping Out — Here's How Sites Are Closing The Gap
- 09.17.26 -- Five Ways To Enrich The Clinical Trial Ecosystem
RECRUITMENT AND DIVERSITY
This section includes some helpful resources regarding patient recruitment and diversity in clinical trials, including this link to the FDA's guidance on diversity action plans.
-
![jackson AI part 2 using-GettyImages-2192428169]( "Turn AI Visibility Into Action: Build Explanation Layers For Different Stakeholders")
AI visibility isn’t just about being found. Ross Jackson coaches sponsors on how to influence AI to provide clear stakeholder pathways for clinical trial involvement.
-
![online question and answer, problem-solving, and digital communication-GettyImages-2241803274]( "Your Trial Shows Up In AI. Now What?")
AI can explain your trial — but can it help patients act? Ross Jackson shares how sponsors can turn visibility into trust and next steps.
-
![nurse and patient-GettyImages-1196843513]( "Sustainable Patient Engagement: Your Enrollment And Representation Depend On It")
Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.
FOCUS ON PATIENTS
-
![business man looking through telescope-GettyImages-2215651052]( "Why Oncology Programs Can't Rely On An Inside View Alone")
Discover how looking outside a program can help oncology teams test assumptions, improve feasibility, and make stronger development decisions.
-
![Risk Assessment-GettyImages-2192813165]( "The Promise Of MRD-Guided CAR-T Treatment")
Minimal residual disease markers can reveal relapse before clinical signs appear, when off-the-shelf cell therapy may have its greatest advantage.
-
![pharmacist, service, guidance, patient care-GettyImages-2260105068]( "The Pharmacy Benefit No One Is Managing: Clinical Research As A Care Option")
Pharmacies could make trials more accessible — if they preserve patient trust while research partners handle the operational burden.
